The anti‐TSLP monoclonal antibody tezepelumab has demonstrated remarkable efficacy in Phase I and II clinical trials, exhibiting improvements in pulmonary function, reduction of eosinophils, and alleviation of asthma symptoms [22]. Here, TSLP is linked to asthma.